BR112014023952A2 - formulações de agentes de ligação à base de igg4 estáveis - Google Patents

formulações de agentes de ligação à base de igg4 estáveis

Info

Publication number
BR112014023952A2
BR112014023952A2 BR112014023952A BR112014023952A BR112014023952A2 BR 112014023952 A2 BR112014023952 A2 BR 112014023952A2 BR 112014023952 A BR112014023952 A BR 112014023952A BR 112014023952 A BR112014023952 A BR 112014023952A BR 112014023952 A2 BR112014023952 A2 BR 112014023952A2
Authority
BR
Brazil
Prior art keywords
binding agent
formulations
igg4
based binding
stable
Prior art date
Application number
BR112014023952A
Other languages
English (en)
Other versions
BR112014023952B1 (pt
Inventor
Youssef Ahmed
Hagendorf Annika
Usener Dirk
Schnieders Julia
Kirsch Martina
Ruggeberg Sabrina
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BR112014023952A2 publication Critical patent/BR112014023952A2/pt
Publication of BR112014023952B1 publication Critical patent/BR112014023952B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

resumo patente de invenção: "formulações de agentes de ligação à base de igg4 estáveis". a presente invenção refere-se a formulações farmacêuticas estáveis de anticorpo, incluindo formulações líquidas de produtos medicamentosos e formulações liofilizadas de produtos medicamentosos, compreendendo um agente de ligação à igg4 e um tampão citrato, onde o ph da formulação é menor ou igual a ph 6 e ao pi do agente de ligação. as formulações podem ser usadas no tratamento de doenças intestinais crônicas ou artrite reumatoide. 22505394v1
BR112014023952-5A 2012-03-26 2013-03-26 Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios BR112014023952B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261615539P 2012-03-26 2012-03-26
US61/615,539 2012-03-26
FR1351013 2013-02-06
FR1351013 2013-02-06
PCT/US2013/033881 WO2013148686A2 (en) 2012-03-26 2013-03-26 Stable igg4 binding agent formulations

Publications (2)

Publication Number Publication Date
BR112014023952A2 true BR112014023952A2 (pt) 2017-07-18
BR112014023952B1 BR112014023952B1 (pt) 2023-01-24

Family

ID=49261390

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112014023952-5A BR112014023952B1 (pt) 2012-03-26 2013-03-26 Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios
BR122019026701-4A BR122019026701B1 (pt) 2012-03-26 2013-03-26 Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122019026701-4A BR122019026701B1 (pt) 2012-03-26 2013-03-26 Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios

Country Status (7)

Country Link
EP (2) EP3431104A1 (pt)
JP (1) JP6265970B2 (pt)
BR (2) BR112014023952B1 (pt)
CA (3) CA2868401C (pt)
PL (1) PL2830658T3 (pt)
RU (1) RU2644214C2 (pt)
WO (1) WO2013148686A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201608323D0 (en) * 2016-05-12 2016-06-29 Ucb Biopharma Sprl Pharmaceutical compositions
CN107446044B (zh) * 2016-05-30 2021-04-30 越海百奥药业(绍兴)有限公司 一种纯化抗体的方法及所用缓冲液
TWI760345B (zh) * 2016-07-05 2022-04-11 法商賽諾菲公司 抗體調配物
SG11201900043TA (en) 2016-07-05 2019-02-27 Sanofi Sa Antibody formulations
CN109963935A (zh) * 2016-11-11 2019-07-02 拜耳股份公司 用于采样流体流以监测连续流动中的污染物的方法
WO2018094404A1 (en) * 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
WO2018158332A1 (en) * 2017-03-01 2018-09-07 Medimmune Limited Formulations of monoclonal antibodies
TW202228779A (zh) 2017-03-01 2022-08-01 英商梅迪繆思有限公司 抗rsv單株抗體配製物
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2966592B2 (ja) * 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
EP3578168A1 (en) * 2002-02-14 2019-12-11 Chugai Seiyaku Kabushiki Kaisha Formulation of antibody-containing solutions comprising a sugar as a stabilizer
US8658773B2 (en) * 2011-05-02 2014-02-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
CN103040732B (zh) * 2003-02-10 2015-04-01 伊兰药品公司 免疫球蛋白制剂及其制备方法
EP1532983A1 (en) * 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
TW200621282A (en) * 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
WO2006042333A2 (en) 2004-10-12 2006-04-20 Xencor, Inc. Prediction and assessment of immunogenicity
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
NZ571757A (en) * 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
JP5209625B2 (ja) 2006-08-28 2013-06-12 協和発酵キリン株式会社 アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
PT2195023T (pt) 2007-08-29 2018-06-08 Sanofi Sa Anticorpos anti-cxcr5 humanizados, seus derivados e suas utilizações

Also Published As

Publication number Publication date
BR122019026701B1 (pt) 2023-01-24
JP6265970B2 (ja) 2018-01-24
CA3123252C (en) 2023-08-22
RU2014142990A (ru) 2016-05-20
BR112014023952B1 (pt) 2023-01-24
CA2868401C (en) 2021-08-24
WO2013148686A3 (en) 2013-11-28
PL2830658T3 (pl) 2019-02-28
CA3204402A1 (en) 2013-10-03
JP2015514090A (ja) 2015-05-18
CA3123252A1 (en) 2013-10-03
EP2830658A2 (en) 2015-02-04
RU2644214C2 (ru) 2018-02-08
WO2013148686A2 (en) 2013-10-03
CA2868401A1 (en) 2013-10-03
EP3431104A1 (en) 2019-01-23
EP2830658B1 (en) 2018-10-10

Similar Documents

Publication Publication Date Title
BR112014023952A2 (pt) formulações de agentes de ligação à base de igg4 estáveis
CY1119140T1 (el) Συνθεσεις αντικωδικευσης και μεθοδοι κατασκευης και χρησης τους
CL2017000829A1 (es) Formulación farmacéutica que comprende mezcla de anticuerpo anti-alfa4beta7, un agente tamponante, y citrato; uso de dicha formulación para tratar enfermedad inflamatoria del intestino.
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
BR112015014372A2 (pt) inibidores de autotaxina
BR112012027034A2 (pt) inibidores da arginase e suas aplicações terapêuticas
MA43709A (fr) Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
BR112018008805A2 (pt) proteínas de função dupla e composição farmacêutica que compreende a mesma
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BR112015018168A2 (pt) inibidores de rock suaves
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
BR112014012056A8 (pt) compostos farmacêuticos
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
FR2961814B1 (fr) Nouveaux peptides activateurs de la sirtuine 6 et composition cosmetique ou pharmaceutiques les comprenant.
MA43918A (fr) Composition pharmaceutique pour la prã‰vention et/ou le traitement de la dermatite atopique contenant comme principe actif un antagoniste de l'il-31
BR112015030229A8 (pt) Partícula semelhante a vírus compreendendo um polipeptídeo e um antígeno da malária, vetor, composições farmacêutica e de vacina, bem como molécula de ácido nucleico isolado
BR112015019412A2 (pt) inibidores de bace1
BR112017018328A2 (pt) anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo
EA201500112A1 (ru) 3-замещенные производные эстра-1,3,5(10),16-тетраена, способы их получения, фармацевтические средства, которые их содержат, и их использование для получения лекарственных средств
UA118576C2 (uk) Фармацевтична композиція, яка містить бринзоламід

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/03/2013, OBSERVADAS AS CONDICOES LEGAIS